Clinical-chemistry laboratory relevant hemolysis is unlikely to compromise human plasma concentration of free asymmetric dimethylarginine (ADMA)

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1536-1538

  Tsikas, Dimitrios ^a   Böhmer, Anke ^a   Großkopf, Henning ^a   Beckmann, Bibiana ^a   Dreißigacker, Ulrike ^a   Jordan, Jens ^a   Maassen, Norbert ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HEMOGLOBIN; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; PLASMA PROTEIN;

BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL CHEMISTRY; ERYTHROCYTE; HEMOLYSIS; HUMAN; LETTER; MASS FRAGMENTOGRAPHY; OXIDATIVE STRESS; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE;

ARGININE; BLOOD CHEMICAL ANALYSIS; BLOOD PROTEINS; ERYTHROCYTES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEMOLYSIS; HUMANS; MALE; PROTEOLYSIS; REFERENCE STANDARDS;

EID: 84868301281     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.03.020     Document Type: Letter

References (15)

1. Zinellu A., Sotgia S., Scanu B., et al. Assessment of protein-incorporated arginine methylation in biological specimens by CZE UV-detection. Electrophoresis 2007, 28:4452-4458.
2. Zinellu A., Sotgia S., Scanu B., et al. Determination of protein-incorporated methylated arginine reference values in healthy subjects whole blood and evaluation of factors affecting protein methylation. Clin Biochem 2008, 41:1218-1223.
3. Leiper J.M., Vallance P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 2006, 62:33-38.
4. Lenzen H., Tsikas D., Böger R.H. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease. The multicenter CARDIAC study. Eur J Clin Pharmacol 2006, 62:45-49.
5. Tsikas D., Beckmann B. Albumin from human serum does not contain asymmetric dimethylarginine (ADMA). Clin Biochem 2009, 42:1739-1740.
6. Tsikas D., Engeli S., Beckmann B., Jordan J. Asymmetric dimethylarginine (ADMA) is present in plasma proteins of healthy subjects at the low nmol-per-g-level. Nitric Oxide 2010, 22:316-317.
7. Böhmer A, Großkopf H, Jordan J, Tsikas D. Human hemoglobin does not contain asymmetric dimethylarginine (ADMA). Nitric Oxide in press, doi:. doi:10.1016/j.niox.2012.03.013.
8. Davids M., van Hell A.J., Visser M., Nijveldt R.J., van Leeuwen P.A.M., Teerlink T. Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am J Physiol Heart Circ Physiol 2012, 10.1152/alpheart.01205.2011.
9. Lippi G., Blanckaert N., Bonini P., Green S., Kitchen S., Palicka V., Vassault A.J., Plebani M. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 2008, 46:764-772.
10. Plebani M., Lippi G. Hemolysis index: quality indicator or criterion for sample rejection?. Clin Chem Lab Med 2009, 47:899-902.
11. Dreissigacker U., Suchy M.T., Maassen N., Tsikas D. Human plasma concentrations of malondialdehyde (MDA) and the F2-isoprostane 15(S)-8-iso-PGF2a may be markedly compromised by hemolysis: evidence by GC-MS/MS and potential analytical and biological ramifications. Clin Biochem 2010, 43:159-167.
12. Tsikas D. A critical review and discussion of analytical methods in the l-arginine/nitric oxide area of basic and clinical research. Anal Biochem 2008, 379:139-163.
13. Tsikas D., Schubert B., Gutzki F.M., et al. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. J Chromatogr B 2003, 798:87-99.
14. Maassen N., Foerster M., Mairbaurl H. Red blood cells do not contribute to removal of K+ released from exhaustively working forearm muscle. J Appl Physiol 1998, 85:326-332.
15. Horowitz J.D., Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B 2007, 851:42-50.